Alireza Atri, MD
Neurological Surgery · Boston, MANPI 1326038506
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $333,869 of the $502,543 with a category attached, or 66.4%. It is spread thinly across 19 manufacturers, the largest accounting for just 18.5%. Reporting peaked in 2023 at $136,801 and has fallen 83.2% since, to $23,000 in 2025. Among neurological surgery clinicians in MA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 268 payments — averaging $1875.16 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- H. Lundbeck A S$93K
- Eisai Inc.$92K
- Biogen$86K
- Novo Nordisk$52K
- Novo Nordisk AS$52K
- Acadia Pharmaceuticals Inc$32K
- plus $96K from 13 others
Across 68 payments — averaging $18,778 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Eli Lilly$611K
- Eisai Inc.$491K
- Genentech, Inc.$57K
- Novartis$38K
- AbbVie$36K
- Biogen$23K
- plus $22K from 3 others
What the payments were for
- Consulting fees$333,86966%
- Speaking & faculty fees$108,72022%
- Travel & lodging$52,38210%
- Food & beverage$7,5722%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| H. Lundbeck A S | 17 | $93,135 |
| Eisai Inc. | 67 | $92,121 |
| Biogen | 18 | $85,675 |
| Novo Nordisk | 27 | $52,182 |
| Novo Nordisk AS | 15 | $51,996 |
| Acadia Pharmaceuticals Inc | 19 | $31,568 |
| Grifols Shared Services North America, Inc. | 14 | $26,036 |
| Genentech USA, Inc. | 13 | $18,538 |
| Roche Products Limited | 5 | $13,073 |
| Lundbeck LLC | 13 | $11,911 |
| Merck | 15 | $8,617 |
| Axsome Therapeutics, Inc. | 6 | $8,232 |
| Genentech, Inc. | 2 | $5,200 |
| Otsuka America Pharmaceutical, Inc. | 24 | $2,473 |
| Grifols Biologicals LLC | 4 | $825 |
| Janssen Global Services, LLC | 6 | $778 |
| Life Molecular Imaging Ltd | 1 | $93 |
| F. Hoffmann-la Roche AG | 1 | $73 |
| Lilly USA, LLC | 1 | $18 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- REXULTI$58,879
- Leqembi$40,089
- NUPLAZID$27,044
- Flebogamma DIF$25,400
- Albutein$20,803
- ADUHELM$12,559
- Non-Covered Product$7,069
- DISEASE EDUCATION$4,240
How this compares
$502,543 in reported general payments places this provider in the 95th percentile of 183 neurological surgery providers in Massachusetts.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Donepezil Hcl | 12 | $249 |
Paid to pharmacies, not to this prescriber.
Other neurological surgery in Boston
- Simcha WellerBoston$905K
- Aman PatelBoston$734K
- Myron RolleBoston$290K
- John ChiBoston$280K
- Philipp TausskyBoston$224K
- Robert RichardsonBoston$190K
- Brendon BootBoston$149K
- Muhammad Abd-El-BarrBoston$140K
- Brian NahedBoston$97K
- Thomas NohBoston$69K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.